Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase vs Alteplase in Acute Ischemic Stroke (EXTEND-IA TNK)
NCT02388061Phase 2Completed
- Sponsor
- Neuroscience Trials Australia
- Start
- Mar 2015
- Primary completion
- Oct 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tenecteplase in ischemic stroke, sponsored by Neuroscience Trials Australia. Primary endpoint: Modified Treatment in Cerebral Ischemia at 0 days. Started Mar 2015; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02388061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388061.